

Erratum. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome

Helena J. Teede^{1,2,3,*}, Marie L. Misso^{1,2,3}, Michael F. Costello⁴, Anuja Dokras⁵, Joop Laven⁶, Lisa Moran^{1,2,3}, Terhi Piltonen⁷, and Robert J. Norman^{1,2,8}, on behalf of the International PCOS Network

¹National Health and Medical Research Council Centre for Research Excellence in PCOS, Monash University, Melbourne, Victoria, Australia ²National Health and Medical Research Council Centre for Research Excellence in PCOS, University of Adelaide, Adelaide, South Australia, Australia ³Monash Centre for Health Research and Implementation, Monash Public Health and Preventive Medicine, Monash University and Monash Health, Melbourne, Victoria, Australia ⁴School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia ⁵Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA ⁶Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus Medical Centre, Rotterdam, The Netherlands ⁷Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Centre, Oulu University Hospital, Oulu, Finland ⁸Robinson Research Institute, University of Adelaide and Fertility SA, Adelaide, Australia

*Correspondence address. Locked Bag 29, Clayton, 3168 Victoria, Australia. Email: helena.teede@monash.edu

Hum Reprod 2018;**33**:1602–1618

The journal, *Human Reproduction*, would like to apologise for an error under the sub-section Biochemical hyperandrogenism of Table III in the above article. The following statement:

Where assessment of biochemical hyperandrogenism is important in women on hormonal contraception, drug withdrawal is recommended for months or longer before measurement, and contraception management with a non-hormonal alternative is needed during this time.

Should read:

Where assessment of biochemical hyperandrogenism is important in women on hormonal contraception, drug withdrawal is recommended for 3 months or longer before measurement, and contraception management with a non-hormonal alternative is needed during this time.

The electronic version of this article has been updated at <https://doi.org/10.1093/humrep/dey256>. The Journal would like to assure readers that this does not affect any other content of the article.